Utility of [11C]4DST PET in assessing malignancy of tumors

JRCT ID: jRCTs031180299

Registered date:15/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Brain tumor, head and neck tumor, lung cancer, liver carcinoma, biliary tract cancer, pancreas cance
• Date of first enrollment: 08/12/2017
• Target sample size: 60
• Study type: Interventional
• Intervention(s): [11C]4DST-PET and FDG-PET are conducted at Southern TOHOKU Medical Clinic as an outpatient. Three hundred seventy MBq of [11C]4DST is administerd as a standard dose and scanning of local lesion(whole body as necessary) is performed 20 min after the end of administration. FDG is administered less than 4MBq/kg of a standard dose and scanning of local lesion(whole body as necessary) is performed 90 min after the end of administration.

Outcome(s)

• Primary Outcome: [11C]4DST uptake in tumors(visual assessment, SUV quantification, uptake count)

Secondary Outcome

1.Histological malignancy
2.FDG uptake in tumors

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1.Patients who have malignant tumors or are suspected to have malignant tumors.
2.Patients who agree and write informed consent form.

Exclude criteria

1.Patients who are assumed to be difficult to implement the PET/CT examination due to general condition etc.
2.Women who are pregnant
3.Other patients who are judged inappropriate by researcher, etc.

Related Information

• Primary Sponsor: Saginoya Toshiyuki
• Secondary ID(s): UMIN000035956